Steele-Warrick v. Microgenics Corporation

CourtDistrict Court, E.D. New York
DecidedApril 26, 2023
Docket1:19-cv-06558
StatusUnknown

This text of Steele-Warrick v. Microgenics Corporation (Steele-Warrick v. Microgenics Corporation) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Steele-Warrick v. Microgenics Corporation, (E.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------------------x NADEZDA STEELE-WARRICK and DARRYL SCHULTZ, individually and on behalf of all others similarly situated,

Plaintiffs,

-against- OPINION Case No. 19-CV-6558-FB-VMS MICROGENICS CORPORATION, THERMO FISHER SCIENTIFIC, INC., ANTHONY ANNUCCI, JAMES O’GORMAN, CHARLES KELLY, RICHARD FINNEGAN, DONALD VENETTOZZI, ANTHONY RODRIGUEZ, COREY BEDARD, and JENNIFER BOOTH,

Defendants. ------------------------------------------------x Appearances: For the Plaintiffs: For Defendants Annucci and MATTHEW D. BRINCKERHOFF O’Gorman: Emery Celli Brinckerhoff Abady Ward SARANDE DEDUSHI & Maazel LLP Assistant Attorney General 600 Fifth Avenue, 10th Floor State of New York New York, New York 10020 28 Liberty Street New York, New York 10005 KAREN L. MURTAGH Prisoners’ Legal Services of New York For Defendants Venettozzi, Rodriguez, 41 State Street, Suite M112 and Booth: Albany, New York 12207 ORIANA L. KILEY Whiteman Osterman & Hanna, LLP One Commerce Plaza Albany, New York 12260 For Defendant Kelly: JEFFREY P. MANS Law Office of Jeffrey P. Mans Post Office Box 11-282 Albany, New York 12211-0202

For Defendant Finnegan: BENJAMIN W. HILL Capezza Hill, LLP 30 South Pearl Street, P-110 Albany, New York 12207

For Defendant Bedard: RYAN T. DONOVAN Conway, Donovan & Manley, PLLC 50 State Street, 2nd Floor Albany, New York 12207

BLOCK, Senior District Judge: In this putative class action under 42 U.S.C. § 1983, Nadezda Steele- Warrick and Darryl Schultz (collectively, “Plaintiffs”) claim that they and thousands of others under the jurisdiction of the New York State Department of Corrections and Community Supervision (“DOCCS”) were subject to discipline based on false-positive results of faulty drug tests developed by Microgenics Corporation and Thermo Fisher Scientific, Inc. (collectively, “Microgenics Defendants”). In addition to the Microgenics Defendants, Plaintiffs have sued eight current and former DOCCS employees (collectively, “DOCCS Defendants”). They allege that those defendants violated their rights under the Eighth

2 Amendment and the Substantive Due Process Clause of the Fourteenth Amendment because they failed to take corrective action after becoming aware that

the tests were unreliable. All the DOCCS Defendants have moved, pursuant to Federal Rule of Civil Procedure 12(b)(6), to dismiss the claims against them. In an order dated March

31, 2023, the motions were summarily granted in part and denied in part. As now explained in the following opinion, the Court concluded that: (1) Plaintiffs do not have a viable Eighth Amendment claim against any of the DOCCS Defendants, (2) Plaintiffs have alleged a cognizable substantive due process claim against five of

the eight DOCCS Defendants, and (3) qualified immunity does not shield those defendants from liability. I

The following facts are taken from the Third Amended Complaint (“Complaint”) and are accepted as true for purposes of the DOCCS Defendants’ Rule 12(b)(6) motions to dismiss. See Erickson v. Pardus, 551 U.S. 89, 94 (2007). The Court assumes the parties’ familiarity with the allegations and recounts only

those pertinent to resolving the motions. Greater detail of the allegations against each DOCCS Defendant is provided as necessary in Part II.1

1 For a detailed recitation of the allegations against the Microgenics

3 A. DOCCS’ Testing System DOCCS Defendant Lieutenant Corey Bedard was charged with overseeing

the DOCCS drug testing program for inmates from 2011 until 2019. Prior to 2016, DOCCS secured testing services from Siemens AG and developed a close working relationship with its employee Brenda Collum, who is not a party to this suit.

Collum left Siemens to work for the Microgenics Defendants in November 2015. She emailed Bedard to suggest that DOCCS consider using her new employer’s services. Bedard then recommended the switch from Siemens to his supervisors, including DOCCS Defendant and Assistant Commissioner of Special

Housing and Inmate Disciplinary Programs Charles Kelly. In 2017, DOCCS conducted a side-by-side comparison of Siemens’s tests and the Microgenics Defendants’ “Indiko Plus” tests. The Indiko Plus test for the

opioid buprenorphine identified one sample as positive that the Siemens’ test did not. The sample was provided by an inmate using codeine, a different opioid, pursuant to a prescription. This misidentification did not cause Bedard any concern; he simply “accepted the Microgenics Defendants’ explanation that the

Defendants, see Magistrate Judge Scanlon’s memorandum and order on their motion to dismiss a prior iteration of the Complaint. Steele-Warrick v. Microgenics Corp., 2021 WL 1109052 (E.D.N.Y. Mar. 22, 2021). The Microgenics Defendants’ motion to dismiss the current Complaint is pending before the Court and is not addressed in this opinion.

4 supposedly more accurate and sensitive [Indiko Plus] assay would solve any such cross-reactivity problems and would be appropriate to discipline incarcerated

individuals.” Complaint ¶ 284. An initial contract between DOCCS and the Microgenics Defendants was cancelled due to flaws in the bidding process. But in September 2018, DOCCS

awarded a contract to the Microgenics Defendants to provide Indiko Plus urinalysis analyzers and related services for correctional facilities in New York. Bedard then worked with Collum to draft a DOCCS directive to use Indiko Plus tests. Bedard passed the directive up the chain of command to DOCCS Defendants Anthony

Rodriguez, Donald E. Venettozzi and Richard Finnegan. The Complaint alleges that all three knew that the Indiko Plus test had misidentified codeine as buprenorphine but did not question or change the directive.

DOCCS Defendant and Deputy Commissioner James O’Gorman signed the directive in December 2018. A month later, DOCCS began using the Indiko Plus tests at all 52 of its facilities. At the same time, DOCCS Defendant Jennifer Booth took over for Bedard as the de facto liaison between the Microgenics Defendants

and DOCCS.

5 B. Steele-Warrick Steele-Warrick was an inmate at DOCCS’s Albion Correctional Facility

(“Albion”). As a result of good behavior, she lived in preferred housing and participated in the Family Reunification Program (“FRP”), which allowed her to meet privately and spend overnight visits with family members.

Steele-Warrick was subject to a urinalysis test before and after each FRP visit. On April 14, 2019, she submitted to an Indiko Plus test. Prior to the test, Steele-Warrick had heard reports of false positives from other inmates and from DOCCS corrections officers, who told her that “they believed something was

wrong with the [testing] machines.” Complaint ¶ 102. Steele-Warrick’s April 14 sample tested positive for Suboxone/buprenorphine. As a result, DOCCS confined Steele-Warrick in a

disciplinary “keeplock” cell for eleven days. Unlike her private room, the keeplock cell was locked behind steel bars and lacked a nightstand, radio, and closet. While in keeplock, her commissary, phone, correspondence, package and visitor privileges were suspended. During her first day in keeplock, she did not

even have access to soap, shampoo or a toothbrush. In addition to punitive confinement, the positive drug test led to a formal disciplinary charge. After a hearing, Steele-Warrick was sentenced to “time

6 served” with an additional thirty-day suspension of package, commissary and recreation privileges.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Chrysler LLC
576 F.3d 108 (Second Circuit, 2009)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Rhodes v. Chapman
452 U.S. 337 (Supreme Court, 1981)
Whitley v. Albers
475 U.S. 312 (Supreme Court, 1986)
Malley v. Briggs
475 U.S. 335 (Supreme Court, 1986)
Chapman v. United States
500 U.S. 453 (Supreme Court, 1991)
Foucha v. Louisiana
504 U.S. 71 (Supreme Court, 1992)
Sandin v. Conner
515 U.S. 472 (Supreme Court, 1995)
County of Sacramento v. Lewis
523 U.S. 833 (Supreme Court, 1998)
Hope v. Pelzer
536 U.S. 730 (Supreme Court, 2002)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Pearson v. Callahan
555 U.S. 223 (Supreme Court, 2009)
Sample v. Diecks
885 F.2d 1099 (Third Circuit, 1989)
United States v. John Walsh
194 F.3d 37 (Second Circuit, 1999)
Mckenna v. Wright
386 F.3d 432 (Second Circuit, 2004)
Southerland v. City of New York
680 F.3d 127 (Second Circuit, 2012)
Gonzalez v. City of Schenectady
728 F.3d 149 (Second Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Steele-Warrick v. Microgenics Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/steele-warrick-v-microgenics-corporation-nyed-2023.